相关实验视频
Updated: Sep 10, 2025

08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
16.1K
葡萄糖受体缺乏导致早期肝硬化
Tessa M Cacciottolo1, Katherine Lawler1, Kevin M Méndez-Acevedo1
1University of Cambridge Metabolic Research Laboratories and National Institute for Health Research Cambridge Biomedical Research Centre, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, U.K.
Diabetes
|August 25, 2025
概括
葡萄糖受体 (GCGR) 基因的遗传变异与血缘家族的肝硬化和肝硬化有关. 这些发现表明可能的治疗策略涉及GCGR调节.
科学领域:
- 遗传学
- 代谢疾病
- 肝病学
背景情况:
- 在正常体重的个体中,肝硬化和肝硬化也可能发生.
- 血缘关系家庭提供了独特的遗传研究机会.
研究的目的:
- 在血缘关系中确定肝硬化和肝硬化的遗传原因.
- 了解已识别的基因变异对葡萄糖受体 (GCGR) 活性和脂质代谢的功能影响.
主要方法:
- 使用全外体测序来识别遗传变异.
- 进行分离分析以确认变体与表型的共分离.
- 用细胞测试来评估GCGR突变的功能后果.
主要成果:
- 在葡萄糖受体 (GCGR) 基因中发现了两种罕见的同卵性变异.
- 这些GCGR变异与肝硬化和肝硬化在家族内共存.
- 实验室研究表明,GCGR突变导致细胞功能丧失和脂肪积累增加.
结论:
- 葡萄糖受体 (GCGR) 基因的功能丧失突变可能导致肝硬化和肝硬化.
- GCGR抗剂可能会导致脂肪肝疾病的风险.
- 在代谢性肝脏疾病中,GCGR激动剂可能具有治疗效益.
相关概念视频
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Hypoglycemia and Glucagon
334
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
334
Glucose Transporters
24.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.1K
Insulin: The Receptor and Signaling Pathways
1.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.5K
Inborn Errors of Metabolism
241
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
241
Hormones Regulating Blood Glucose
4.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.0K

